Brazil approves ocrelizumab treatment for young multiple sclerosis patients

The Brazilian National Health Surveillance Agency (Anvisa) has expanded the use of the drug ocrelizumab, authorizing its use for multiple sclerosis…

This treatment, which is administered for the relapsing-remitting type known as the most common form of the disease, stands out as a new hope for young patients.